Allchem Lifescience, a Gujarat-based producer specializing in energetic pharmaceutical ingredient (API) intermediates and specialty chemical substances, has filed preliminary papers with the Securities and Trade Board of India (SEBI) looking for approval for an preliminary public providing (IPO).
The proposed IPO features a recent difficulty of fairness shares totaling as much as ₹190 crore and a suggestion on the market (OFS) of 71.55 lakh fairness shares by promoters Kantilal Ramanlal Patel and Manisha Bipin Patel.
The corporate plans to allocate ₹130 crore from the recent difficulty in the direction of debt compensation, with the remaining funds used for normal company functions and to assist enterprise necessities.
Emkay World Monetary Companies is the only real book-running lead supervisor for the problem.
In regards to the firm
Established in 2017, Allchem Lifescience has developed the aptitude to fabricate 263 merchandise, specializing in varied chemistries in natural compounds.
The corporate is acknowledged for producing piperazine derivatives, important uncooked supplies for APIs like quetiapine, utilized in treating schizophrenia and bipolar dysfunction. Their manufacturing facility is situated in Vadodara, Gujarat, and so they serve each home and worldwide purchasers, together with Alembic Prescribed drugs, Indoco Cures, and Neuland Laboratories.
Financially, Allchem Lifescience’s income from operations grew at a compound annual progress fee (CAGR) of 12.75% between FY22 and FY24.
For the six months ending September 30, 2024, income was ₹7.84 crore. Revenue after tax (PAT) elevated at a CAGR of 28.65% from March 31, 2022, to March 31, 2024, with a PAT of ₹1.09 crore for the six months ending September 2024.
Disclaimer: This story is for academic functions solely. The views and suggestions above are these of particular person analysts or broking firms, not Mint. We advise buyers to verify with licensed consultants earlier than making any funding choices.
